Arrowhead Pharmaceuticals Inc BDR (A2RR34)

Currency in BRL

33.78

-0.39(-1.14%)

Closed·15:54:59

Fair Value

Unlock Value

Day's Range

33.78

34.08

52 wk Range

25.48

59.95

A2RR34 Income Statement

Assess the Arrowhead Pharmaceuticals BDR income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the A2RR34 net worth.

Period Ending:

2016

30/09

2017

30/09

2018

30/09

2019

30/09

2020

30/09

2021

30/09

2022

30/09

2023

30/09

2024

30/09

2025

30/09

Total Revenues

aa.aa

138.29

243.23

240.74

3.55

829.45

Total Revenues Growth

aa.aa

+57.16%

+75.89%

-1.03%

-98.52%

+23,258.15%

Cost Of Revenues

aa.aa

Gross Profit

aa.aa

138.29

243.23

240.74

3.55

829.45

Gross Profit Growth

aa.aa

+57.16%

+75.89%

-1.03%

-98.52%

+23,258.15%

Gross Profit Margin %

aa.aa

100%

Other Operating Expenses, Total

aa.aa

287.32

421.74

445.74

604.63

731.1

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+58.61%	+46.78%	+5.69%	+35.65%	+20.92%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	201.88	289.3	341.66	491.19	592.6
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	85.44	132.44	104.08	113.44	138.5
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-149.04

-178.51

-205

-601.08

98.35

Operating Income Growth

aa.aa

-59.98%

-19.77%

-14.84%

-193.21%

+116.36%

EBIT Margin %

aa.aa

-107.77%

-73.39%

-85.16%

-16,927.06%

11.86%

Net Interest Expenses

aa.aa

6.12

5.03

-3.03

-9.63

-52.07

Net Interest Expenses Growth

aa.aa

-33.41%

-17.76%

-160.14%

-218.2%

-440.61%

Interest Expense, Total

aa.aa

-18.33

-32.35

-89.36

Interest And Investment Income

aa.aa

6.12

5.03

15.3

22.72

37.29

Other Non Operating Expenses, Total

aa.aa

2.07

0.77

1.54

-1.75

5.26

EBT, Excl. Unusual Items

aa.aa

-140.85

-172.71

-206.49

-612.46

51.53

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

EBT, Incl. Unusual Items

aa.aa

-140.85

-172.71

-206.49

-612.46

51.53

EBT, Incl. Unusual Items Growth

aa.aa

-66.58%

-22.62%

-19.56%

-196.6%

+108.41%

EBT, Incl. Unusual Items Margin

aa.aa

-101.85%

-71.01%

-85.78%

-17,247.54%

6.21%

Income Tax Expense

aa.aa

3.79

2.78

-2.77

21.42

Net Income to Company

aa.aa

-140.85

-176.49

-209.28

-609.69

30.11

Minority Interest

aa.aa

0.43

10.2

-31.75

Net Income

aa.aa

-140.85

-176.06

-205.28

-599.49

-1.63

Net Income Growth

aa.aa

-66.58%

-25%

-16.59%

-192.04%

+99.73%

Net Income Margin %

aa.aa

-101.85%

-72.39%

-85.27%

-16,882.37%

-0.2%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-140.85

-176.06

-205.28

-599.49

-1.63

Basic EPS - Continuing Operations

aa.aa

-1.36

-1.67

-1.92

-5

-0.01

Basic EPS - Continuing Operations Growth

aa.aa

-61.73%

-23.01%

-15.15%

-160.27%

+99.76%

Diluted EPS - Continuing Operations

aa.aa

-1.36

-1.67

-1.92

-5

-0.01

Diluted EPS - Continuing Operations Growth

aa.aa

-61.9%

-22.8%

-15.15%

-160.27%

+99.76%

Basic Weighted Average Shares Outstanding

aa.aa

103.75

105.43

106.75

119.78

133.76

Diluted Weighted Average Shares Outstanding

aa.aa

103.75

105.43

106.75

119.78

133.76

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-140.77

-168.09

-192.51

-582.49

122.27

EBITDA Growth

aa.aa

-61.4%

-19.41%

-14.53%

-202.58%

+120.99%

EBITDA Margin %

aa.aa

-101.79%

-69.11%

-79.97%

-16,403.41%

14.74%

EBIT

aa.aa

-149.04

-178.51

-205

-601.08

98.35

* In Millions of USD (except for per share items)

FAQ

What was Arrowhead Pharmaceuticals BDR’s revenue at year end?

At the end of the last reported fiscal year, Arrowhead Pharmaceuticals BDR (A2RR34) recorded total revenue of 829.45 million USD.

How much revenue did Arrowhead Pharmaceuticals BDR report in the most recent quarter?

In its most recent quarterly earnings report, Arrowhead Pharmaceuticals BDR posted revenue of 75.25 million USD.

What was Arrowhead Pharmaceuticals BDR’s net income for the year?

For the full year, Arrowhead Pharmaceuticals BDR reported net income of -1.63 million USD.

How much net income did Arrowhead Pharmaceuticals BDR post in the last quarter?

In the most recent quarter, Arrowhead Pharmaceuticals BDR (A2RR34) posted net income of -194.28 million USD.

What was Arrowhead Pharmaceuticals BDR’s gross profit for the year?

Gross profit for the year was reported at 829.45 million USD.

How much gross profit did Arrowhead Pharmaceuticals BDR generate last quarter?

Arrowhead Pharmaceuticals BDR recorded gross profit of 75.25 million USD in its latest quarterly report.

What was Arrowhead Pharmaceuticals BDR’s annual operating income?

For the full year, Arrowhead Pharmaceuticals BDR (A2RR34) reported operating income of 98.35 million USD.

What was Arrowhead Pharmaceuticals BDR’s operating income last quarter?

Quarterly operating income was -170.09 million USD.

What was Arrowhead Pharmaceuticals BDR’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -163.43 million USD.

What was the quarter-over-quarter change in EBITDA for Arrowhead Pharmaceuticals BDR?

EBITDA changed by -21.16% million USD compared to the last quarter.

What is Arrowhead Pharmaceuticals BDR’s most recent gross profit margin?

The latest reported gross profit margin for Arrowhead Pharmaceuticals BDR (A2RR34) is 100.00% million USD.

What is Arrowhead Pharmaceuticals BDR’s most recent net income margin?

Net income margin based on recent financials is -258.17% million USD.

What is Arrowhead Pharmaceuticals BDR’s most recent EBIT margin?

Arrowhead Pharmaceuticals BDR reported an EBIT margin of -226.03% million USD based on current figures.

How did Arrowhead Pharmaceuticals BDR’s revenue change compared to the previous quarter?

Revenue changed by 2.06% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Arrowhead Pharmaceuticals BDR?

In the latest quarter, gross profit changed by 2.06% million USD from the previous quarter.

S&P/TSX

36,137.19

-274.53

-0.75%

S&P/TSX 60

2,154.60

-10.25

-0.47%

US 30

52,427.30

+128.2

+0.25%

US 500

7,615.80

+22.9

+0.30%

S&P 500 VIX

18.70

+1.21

+6.92%

DAX

26,771.88

+109.11

+0.41%

Dollar Index

103.075

-0.035

-0.03%

Market Movers

Name	Last	Chg. %	Vol.
NVIDIA DRC	36.91	-4.35%	14.98M
Suncor Energy	98.80	+0.60%	5.44M
Enbridge	68.57	+0.47%	7.09M
RBC	289.39	-0.21%	1.62M
TD	176.69	-0.21%	1.96M
Canadian Natural	70.04	+0.50%	4.62M
Bank of Montreal	246.71	-0.42%	1.27M

Name	Last	Chg. %	Vol.
Mijem Newcomm Tech	0.10	+375.00%	27.00K
Sweet Earth Holdings	1.85	+262.75%	134.50K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Tempus Capital	0.1500	+114.29%	8.15K
Spacefy	0.010	+100.00%	4.60K
Pulse Oil	0.01000	+100.00%	163.89K
ePlay Digital	0.010	+100.00%	7.00K

Name	Last	Chg. %	Vol.
Capitan Investment	0.010	-50.00%	83.33K
Molecule Holdings	0.005	-50.00%	20.11K
James Bay Resources Ltd	0.005	-50.00%	35.10K
Albert Labs International	0.005	-50.00%	1.00K
Mary Agrotechnologies	0.01	-50.00%	1.00K
First Growth Funds	0.01	-50.00%	50.00K
Nuinsco Resources	0.0050	-50.00%	127.00K

Trending Stocks

Name	Last	Chg. %	Vol.
NVIDIA DRC	36.86	-4.43%	1.33M
Celestica Inc.	361.92	+4.77%	654.76K
Telus	12.14	-1.54%	5.68M
Keel Infra	2.77	-5.78%	3.15M
MDA	41.71	-5.53%	1.52M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaa Aaaaaaa	9.47	+56.52%	14.82
Aaaa Aaaaaaaaaaaaaa	3.7600	+52.96%	5.7512
Aaaaaa	106.26	+52.71%	162.27
A Aaaaaaa	35.38	+52.27%	53.87
A Aaaaaaaa	18.15	+48.86%	27.02
Aaaaaaaaaaaa	99.37	+48.37%	147.43
A Aaa Aa	24.41	+47.19%	35.93

Name	Last	Upside	Fair Value
Aaaaaaaa Aaaaaaa	9.47	+56.52%	14.82
Aaaa Aaaaaaaaaaaaaa	3.7600	+52.96%	5.7512
Aaaaaa	106.26	+52.71%	162.27
A Aaaaaaa	35.38	+52.27%	53.87
A Aaaaaaaa	18.15	+48.86%	27.02
Aaaaaaaaaaaa	99.37	+48.37%	147.43
A Aaa Aa	24.41	+47.19%	35.93

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.